On Thursday, March 24, Portola announced the top-line results from APEX, a large phase 3 trial of the novel oral anticoagulant betrixaban. With two other Factor Xa inhibitors already on the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results